Detailed information for compound 1826319

Basic information

Technical information
  • Name: Unnamed compound
  • MW: 365.427 | Formula: C24H19N3O
  • H donors: 0 H acceptors: 2 LogP: 5.27 Rotable bonds: 4
    Rule of 5 violations (Lipinski): 1
  • SMILES: Cc1nc2c(n1c1ccccc1)cc(cc2)OCc1ccc2c(n1)cccc2
  • InChi: 1S/C24H19N3O/c1-17-25-23-14-13-21(15-24(23)27(17)20-8-3-2-4-9-20)28-16-19-12-11-18-7-5-6-10-22(18)26-19/h2-15H,16H2,1H3
  • InChiKey: QBYKGPDSZZURMK-UHFFFAOYSA-N  

Network

Hover on a compound node to display the structore

Synonyms

No synonyms found for this compound

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Homo sapiens phosphodiesterase 10A Starlite/ChEMBL References
Homo sapiens cytochrome P450, family 1, subfamily A, polypeptide 2 Starlite/ChEMBL References

Predicted pathogen targets for this compound

By orthology
Species Potential target Known druggable target/s Ortholog Group
Echinococcus granulosus cAMP and cAMP inhibited cGMP 3'5' cyclic Get druggable targets OG5_135363 All targets in OG5_135363
Loa Loa (eye worm) hypothetical protein Get druggable targets OG5_135363 All targets in OG5_135363
Brugia malayi Probable 3',5'-cyclic phosphodiesterase C32E12.2, putative Get druggable targets OG5_135363 All targets in OG5_135363
Echinococcus multilocularis cAMP and cAMP inhibited cGMP 3',5' cyclic Get druggable targets OG5_135363 All targets in OG5_135363
Loa Loa (eye worm) hypothetical protein Get druggable targets OG5_135363 All targets in OG5_135363

By sequence similarity to non orthologous known druggable targets
Species Potential target Known druggable target Length Alignment span Identity
Trypanosoma brucei cAMP-specific phosphodiesterase phosphodiesterase 10A 789 aa 666 aa 30.2 %
Brugia malayi Cytochrome P450 family protein cytochrome P450, family 1, subfamily A, polypeptide 2 516 aa 470 aa 26.2 %

Obtained from network model

Ranking Plot


Putative Targets List


Species Potential target Raw Global Species
Mycobacterium ulcerans putative transglutaminase-like protein 0.0664 1 0.5
Mycobacterium leprae Conserved hypothetical protein 0.0664 1 0.5
Trichomonas vaginalis peptide N-glycanase, putative 0.0664 1 0.5
Schistosoma mansoni hypothetical protein 0.0664 1 0.5
Mycobacterium ulcerans hypothetical protein 0.0664 1 0.5
Giardia lamblia Transglutaminase/protease, putative 0.0664 1 0.5
Giardia lamblia Hypothetical protein 0.0664 1 0.5
Mycobacterium ulcerans transglutaminase family protein 0.0664 1 0.5
Echinococcus multilocularis Transglutaminase 0.0664 1 1
Mycobacterium leprae Conserved hypothetical protein 0.0664 1 0.5
Mycobacterium tuberculosis Long conserved protein 0.0664 1 0.5
Mycobacterium tuberculosis Conserved hypothetical protein 0.0664 1 0.5
Mycobacterium tuberculosis Conserved protein 0.0664 1 0.5
Mycobacterium tuberculosis Hypothetical protein 0.0664 1 0.5
Loa Loa (eye worm) hypothetical protein 0.028 0.0577 1
Mycobacterium tuberculosis Conserved hypothetical protein 0.0664 1 0.5
Mycobacterium ulcerans hypothetical protein 0.0664 1 0.5
Echinococcus granulosus Transglutaminase 0.0664 1 1
Onchocerca volvulus 0.0664 1 0.5

Activities

Activity type Activity value Assay description Source Reference
IC50 (binding) = 305 nM Inhibition of human recombinant full length PDE10A2 expressed in SF9 cells infected with baculovirus expression system using cAMP as substrate incubated 30 mins prior to substrate addition measured after 60 mins by HTRF method ChEMBL. 24238902
IC50 (ADMET) = 0.63 uM Inhibition of CYP1A2 (unknown origin) after 20 mins by fluorescence assay ChEMBL. 24238902

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

1 literature reference was collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.